Hence, further studies are needed to elucidate the clinical value(s) of activins and their related molecules in the pathogenesis of CHC, prediction of the treatment outcome during the use of Peg-INF-α based therapy, and the effect(s) of the new antiviral agents on these immune regulatory proteins. This evidence concerns the gene IFNA17 and cryohydrocytosis.